Given these facts, while acknowledging that this research area remains in its infancy, we feel there is potential for the discovery and development of specific, safe, and effective therapeutics targeting PRMTs for C9orf72 G4C2n-mediated ALS/FTD. This evidence concerns the gene C9orf72 and frontotemporal dementia.